Atlas Trials

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Clinical trial NCT02781558 · COMPLETED

Trial details

NCT number
NCT02781558
Sponsor
Gilead Sciences
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatitis C Virus Infection
Start date
2016-07-29
Primary completion
2017-10-06
Enrollment
204

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.